# Galectin Therapeutics Inc. (GALT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.61, market value $465 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Galectin Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.

## Profitability
- **Return on equity: 24.1%**. 24.1% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.

## Growth
- **EPS growth (1 yr): 36.8%**. Earnings per share rose 36.8%.

## Financial health
- **Current ratio: 2.42** (quick 2.42). Current assets cover the next year's liabilities 2.42 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Galectin Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -1.3%** (YTD 10.8%, 3-mo 97.9%). The shares are down 1.3% over twelve months including dividends.
- **From 52-week high: -35.3%** (127.1% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 68**. An RSI of 68 is neutral.
- **Beta (1 yr): 0.85** (volatility 95%). Beta of 0.85 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GALT · Page: https://foliofundamentals.com/stocks/galt

Not investment advice.